Skip to main navigation Skip to search Skip to main content

Optimality, Future and Terminal Costs: Comment on “Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran”

Research output: Contribution to journalLetterpeer-review

1 Scopus citations
Original languageEnglish
Pages (from-to)383-384
Number of pages2
JournalPharmacoEconomics
Volume36
Issue number3
DOIs
StatePublished - 1 Mar 2018

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

ASJC Scopus subject areas

  • Pharmacology
  • Health Policy
  • Public Health, Environmental and Occupational Health

Cite this